CMV gB Specific Neutra™ Antibody Products

Are you currently facing challenges in antibody development or complex clinical trials? Creative Biolabs' CMV gB Specific Neutra™ Antibody Products help you develop highly specific antibodies and streamline clinical trial processes through innovative protein engineering techniques.

Introduction to CMV gB

Human cytomegalovirus (CMV) is a ubiquitous viral pathogen, alias as human herpesvirus 5. It contributing substantially to neonatal and immunocompromised patient morbidity worldwide. The CMV glycoprotein B (gB) is a key component of the viral envelope. It occupies a central position in vaccine development. gB mediates viral-host membrane fusion, a prerequisite for viral entry into diverse cellular targets. This gB-mediated fusion is critical, facilitating the delivery of viral genetic material into host cells, thereby initiating infection and establishing viral replication.

Structure

Fig. 1 Structural diagram of HCMV gB.^{1, 3}

CMV gB comprises an extensive ectodomain, a transmembrane segment, and a cytoplasmic tail. This glycosylation-rich ectodomain is pivotal for attachment to cellular receptors on the host. The crystal structure of HCMV gB aligns with post fusion configurations observed in other viral glycoproteins, so it is categorized as a class III viral fusogen. The structural insights are essential for deciphering the functional mechanisms of gB and identifying potential sites for antibody intervention.

Related Signaling Pathways

Fig. 2 HCMV glycoprotein-receptor interactions govern viral signaling pathways. ^{2, 3}

CMV gB's interaction with host cell receptors can trigger various signaling pathways within the host cell. These pathways can influence viral entry, replication, and the host's immune response. For instance, CMV manipulates cellular signaling pathways, including the Epidermal Growth Factor Receptor (EGFR) pathway, to promote infection and persistence. Understanding these interactions is vital for developing effective antiviral therapies.

Application of Anti-CMV gB Antibody

Prophylaxis in Transplant Recipients

CMV infection is a serious concern for immunocompromised transplant recipients. Anti-CMV gB antibodies can be used prophylactically to prevent CMV disease. By neutralizing the virus, anti-CMV gB antibodies can reduce the risk of CMV viremia and subsequent end-organ disease. This can lead to significant morbidity and mortality. The approach helps improve transplant outcomes and reduces the need for antiviral drugs.

Prevention of Congenital CMV Infection

Congenital CMV infection, a preeminent source of sensorineural deficits, may be mitigated through immunoglobulin-based prophylaxis targeting viral gB—the fusogenic mediator of CMV's placental tropism. Phase II trials demonstrate hyperimmune globulin (HIG) infusions in seroconverting pregnant women attenuate transplacental virological sieving, via gB-specific neutralization that occludes virion-endothelial cell interactions. This viroprotective immunoglobulin G (IgG) fraction disrupts gB's pH-sensing domains, aborting viral endocytosis in trophoblasts and curtailing neurodevelopmental sequelae. While not sterilizing, such pathogen sequestration in maternal circulation reduces fetal viral loads below neuropathic thresholds, offering a critical interventional window absent licensed vaccines.

Creative Biolabs provides high-quality CMV gB Specific Neutra™ Antibody Products to support your development needs. Our products are designed to accelerate your drug discovery process and streamline your clinical trials. We offer a range of antibodies with high specificity and affinity for CMV gB, enabling you to develop effective strategies for preventing and treating CMV infections.

REFERENCES

1. Burke, Heidi G., and Ekaterina E. Heldwein. "Crystal structure of the human cytomegalovirus glycoprotein B." PLoS pathogens 11.10 (2015): e1005227. https://doi.org/10.1371/journal.ppat.1005227
2. Lee, Byeong-Jae, et al. "Human cytomegalovirus host interactions: EGFR and host cell signaling is a point of convergence between viral infection and functional changes in infected cells." Frontiers in Microbiology 12 (2021): 660901. https://doi.org/10.3389/fmicb.2021.660901
3. Distributed under Open Access license CC BY 4.0, without modification.